MedTrace Logo

3BNC117-LS First-in-Human Phase 1 Study

NCT03254277 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2026-05-20

Study results available
· View outcomes & findings →

Summary

The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single administration of 3BNC117-LS.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

3BNC117-LS

Intravenous infusion of 3BNC117-LS

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Marina Caskey, MD · The Rockefeller University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03254277 on ClinicalTrials.gov